Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sovaldi Stunner: $2.27 Billion In Sales In Its First Full Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Sweeping sales of Gilead’s hepatitis C drug could draw more ire from payers, but Gilead is highlighting the cost of non-treatment to address concerns about the drug’s $1,000-a-day price tag. In the U.S., Sovaldi use has been split fairly evenly between private-sector and government payers, firm says.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel